Examining the Data From Key Clinical Trials, and Practical Strategies

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

In both racial cohorts, median MFS was not reached in the darolutamide group.